Xarelto Regimens Demonstrate Safety for Stented Afib Patients

ACC Conference Reporter

AHA 2016 | NEW ORLEANS — Stenting in the presence of atrial fibrillation (Afib) is a significant clinical challenge, but the challenge may be eased -- and safety increased -- with a novel triple therapy regimen of rivaroxaban (Xarelto), combined with either dual antiplatelet therapy (DAPT) or a P2Y12 inibitor. Read More >>>

Keywords: AHA Annual Scientific Sessions, AHA16

< Back to Listings